230 related articles for article (PubMed ID: 30225540)
1. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma.
Stroese AJ; Ullerich H; Koehler G; Raetzel V; Senninger N; Dhayat SA
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2377-2390. PubMed ID: 30225540
[TBL] [Abstract][Full Text] [Related]
2. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
3. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
6. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Traeger MM; Rehkaemper J; Stroese AJ; Steinestel K; Wardelmann E; Kabar I; Senninger N
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30217058
[TBL] [Abstract][Full Text] [Related]
8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
10. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
11. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
Goto T; Fujiya M; Konishi H; Sasajima J; Fujibayashi S; Hayashi A; Utsumi T; Sato H; Iwama T; Ijiri M; Sakatani A; Tanaka K; Nomura Y; Ueno N; Kashima S; Moriichi K; Mizukami Y; Kohgo Y; Okumura T
BMC Cancer; 2018 Jan; 18(1):116. PubMed ID: 29385987
[TBL] [Abstract][Full Text] [Related]
12. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
[TBL] [Abstract][Full Text] [Related]
13. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
14. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls.
Li A; Yu J; Kim H; Wolfgang CL; Canto MI; Hruban RH; Goggins M
Clin Cancer Res; 2013 Jul; 19(13):3600-10. PubMed ID: 23697990
[TBL] [Abstract][Full Text] [Related]
17. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
18. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
[TBL] [Abstract][Full Text] [Related]
19. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.
Jiang D; Yuan X; Ni J; Shen L; Cai M; Xu L
Can J Gastroenterol Hepatol; 2021; 2021():8882129. PubMed ID: 34222137
[TBL] [Abstract][Full Text] [Related]
20. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
